Eikon Therapeutics presented promising clinical data for its experimental drugs EIK1001 and EIK1003 at the 2026 ASCO Annual Meeting. EIK1001, in combination with standard of care, achieved a 63.1% objective response rate and 90.8% disease control rate in first-line stage 4 NSCLC patients. EIK1003 demonstrated anti-tumor activity as a monotherapy and in combination with paclitaxel in advanced solid tumors, including ovarian and breast cancer, with defined safety profiles.

Eikon Therapeutics presented updated data on its clinical-stage programs, EIK1001 and EIK1003, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The EIK1001 trial in NSCLC showed encouraging response rates and durability, while EIK1003, a PARP1 inhibitor, demonstrated meaningful clinical activity both as a monotherapy and in combination with paclitaxel for advanced solid tumors. These findings reinforce the potential of Eikon's pipeline to deliver significant benefits to cancer patients.

Geode Capital Management slightly increased its stake in Copart Inc. (CPRT) during the fourth quarter, raising its position by 0.6% to approximately 23.26 million shares, valued around $906.8 million. This move highlights significant institutional interest in the online salvage-vehicle auction specialist. The article also notes Copart's trading activity, its business model, and the importance of institutional holdings alongside its 52-week stock price range.

This article provides a comprehensive overview of the Calvert Ultra-Short Investment Grade ETF (CVSB), traded on NYSE American. It details the fund's objective to maximize income and preserve capital through active investment in a variety of investment-grade debt securities, while also considering ESG factors. Key financial data, performance metrics, and frequently asked questions about CVSB are addressed, highlighting its expense ratio, dividend yield, and management style.

Grand Canyon Education Inc. (LOPE) stock has dropped to a 52-week low of $149.24, marking a nearly 23% decline over the past year despite strong fundamentals like a 22% return on assets and more cash than debt. InvestingPro analysis suggests the stock is undervalued, and management's aggressive share buybacks indicate confidence. The company recently exceeded Q1 2026 adjusted EPS expectations but slightly missed revenue forecasts, highlighting an ongoing need for investors to monitor its financial performance in a competitive education services landscape.

Cogent Communications Holdings, Inc. saw its stock price surge by 9.91% today, reaching an intraday high of USD 20.70, outperforming the S&P 500. Despite this daily gain, the company faces significant challenges, including substantial long-term stock declines, high debt levels, negative financial results for four consecutive quarters, and reduced promoter confidence.

BioNTech and Bristol Myers Squibb have released promising interim Phase 2 data from the ROSETTA Lung-02 trial for pumitamig combined with chemotherapy in first-line non-small cell lung cancer (NSCLC). This investigational bispecific immunomodulator demonstrated high objective response rates and a manageable safety profile, suggesting its potential to become a new standard of care. The companies are advancing pumitamig into a comprehensive global Phase 3 development program for various NSCLC subtypes.

BitMine Immersion Technologies (NYSE:BMNR) is transforming into an Ethereum proxy, holding over 4.4% of the total Ethereum supply, including a significant US$230 million purchase, and launching the institutional Ethereum staking platform MAVAN. The company's potential inclusion in major stock indices like the Russell 1000 could further solidify its position as a means for institutional investors to gain exposure to Ethereum through equities. While offering substantial revenue growth potential and asset exposure, investors should be aware of the company's current unprofitability and past shareholder dilution.

ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge up to $160 per barrel due to dwindling inventory levels, despite recent moderation attributed to strategic petroleum reserve releases. This warning came as Exxon shareholders approved a plan to move the company's legal domicile from New Jersey to Texas, aligning its corporate structure with its existing operational presence in the state. CEO Darren Woods cited Texas's strong regulatory environment as a key factor for the relocation.

AT&T is phasing out its copper landline network in 18 states, moving customers to newer technology. This transition is causing concern for long-time landline users, particularly older individuals and those in rural areas, who feel unprepared or uninformed about the changes. The AARP is advocating for better communication, training, and affordable options from telephone companies during this technology shift.